

## **ELAN CORPORATION, PLC (the “Company”)**

Annual Information Document for the period from 12 April 2008 up to and including 16 April 2009. The Company published its annual financial statements in respect of the year ended 31 December 2008 on 31 March 2009.

This Annual Information Document has been prepared by Elan Corporation, plc in accordance with the provisions of Part 11 of the Prospectus (Directive 2003/71/EC) Regulations 2005 (S.I. No. 324 of 2005) and has been submitted to the Irish Stock Exchange for filing with the Irish Financial Services Regulatory Authority (the Financial Regulator) in accordance with the Prospectus Rules issued by the Financial Regulator. The Company is publishing this Annual Information Document via an RIS today and making it available on its website [www.elan.com](http://www.elan.com). The Company does not intend to rely solely on the Financial Regulator to publish the Annual Information Document.

The information referred to in this document was up to date at the time it was published but some information may now be out-of-date. To avoid an unnecessarily lengthy document, information is referred to in this document rather than included in full.

### **1. Announcements made via RIS, a regulatory information service**

All of the announcements listed below were published via RIS, a Regulatory Information Service and are available for viewing on the Irish Stock Exchange website [www.ise.ie](http://www.ise.ie).

<b>Date</b>	<b>Announcement</b>
14/04/2009	Holding(s) in Company
14/04/2009	Elan Announces Webcast of First Quarter 2009 Financial Results
02/04/2009	Elan and Wyeth Plan to Amend Bapineuzumab Phase 3 Protocols
31/03/2009	Total Voting Rights
31/03/2009	Elan Announces Filing of Annual Report for Year Ended December 31, 2008
12/03/2009	Elan to Present at Cowen and Company 29th Annual Health Care Conference
27/02/2009	Total Voting Rights
25/02/2009	Director/PDMR Shareholding
25/02/2009	Director/PDMR Shareholding
25/02/2009	Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process
18/02/2009	Director/PDMR Shareholding
18/02/2009	Director/PDMR Shareholding
12/02/2009	Director/PDMR Shareholding
12/02/2009	Director/PDMR Shareholding
12/02/2009	Director/PDMR Shareholding
12/02/2009	Director/PDMR Shareholding
12/02/2009	Director/PDMR Shareholding
10/02/2009	Elan Reports Fourth Quarter and Full-Year 2008 Results
09/02/2009	MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
04/02/2009	Holding(s) in Company
03/02/2009	Holding(s) in Company
30/01/2009	Holding(s) in Company
30/01/2009	Total Voting Rights
28/01/2009	Holding(s) in Company
13/01/2009	Elan clarifies duration of Bapineuzumab Phase 3 trials
13/01/2009	Elan to Review Strategic Business Alternatives
13/01/2009	Elan Clarifies Duration of Bapineuzumab Phase 3 Trials
12/01/2009	Holding(s) in Company
12/01/2009	Elan Announces Webcast of Fourth Quarter and Full Year 2008 Financial Results
12/01/2009	Tysabri Update
02/01/2009	Total Voting Rights
18/12/2008	Block Listing Six Monthly Return

16/12/2008 Director Declaration  
 16/12/2008 Elan to Present at the 27th Annual JP Morgan Healthcare Conference  
 15/12/2008 Tysabri Update  
 12/12/2008 Elan Announces Resource Realignment  
 28/11/2008 Total Voting Rights  
 25/11/2008 Mary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations  
 20/11/2008 Carlos V. Paya, MD, PhD, to Join Elan as Company President  
 03/11/2008 Director/PDMR Shareholding  
 03/11/2008 Notification of Change in Director's Details  
 31/10/2008 Holding in Company  
 31/10/2008 Total Voting Rights  
 30/10/2008 Tysabri Update  
 28/10/2008 Elan to Present at 2008 DB-Biotech Boston Confab  
 28/10/2008 Elan to Present at 2008 DB-Biotech Boston Confab  
 23/10/2008 Elan Reports Third Quarter 2008 Financial Results  
 03/10/2008 Holding in Company  
 30/09/2008 Total Voting Rights  
 30/09/2008 Elan Announces Dates for Upcoming Corporate Events  
 22/09/2008 Holding In Company  
 22/09/2008 Tysabri Demonstrates Sustained Improvement  
 22/09/2008 TYSABRI(R) Demonstrates Sustained Improvement in Functional Outcomes in Multiple Sclerosis Patients According to New Post-Hoc Analysis  
 11/09/2008 Director /PDMR Shareholding  
 05/09/2008 Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology  
 01/09/2008 Holding(s) in Company  
 29/08/2008 Total Voting Rights  
 28/08/2008 Interim Results  
 14/08/2008 Holding in Company  
 13/08/2008 Holding in Company  
 06/08/2008 Directors/PDMR Shareholding  
 05/08/2008 Holding in Company  
 05/08/2008 Directors/PDMR Shareholding  
 05/08/2008 Holding(s) in Company  
 01/08/2008 Holding in Company  
 01/08/2008 Holding in Company  
 01/08/2008 FURTHER INFORMATION RE: TYSABRI  
 01/08/2008 Biogen Idec and Elan Will Host a Conference Call For the Investment Community  
 31/07/2008 Total Voting Rights  
 24/07/2008 Elan Reports Second Quarter 2008 Financial Results  
 22/07/2008 Elan and Wyeth Announce Webcast To Discuss Bapineuzumab Phase 2 Clinical Trial Results  
 22/07/2008 Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis  
 14/07/2008 Holding in Company  
 09/07/2008 Holding in Company  
 08/07/2008 Holding in Company  
 07/07/2008 Elan Announces Webcast of Second Quarter 2008 Financial Results  
 04/07/2008 Holding in Company  
 02/07/2008 Holding(s) in Company  
 30/06/2008 Total Voting Rights  
 27/06/2008 Notification of Change in Director's Details  
 25/06/2008 Holding in Company  
 20/06/2008 Director/PDMR Shareholdings  
 20/06/2008 Director/PDMR Shareholdings  
 19/06/2008 Holding in Company  
 17/06/2008 Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease  
 13/06/2008 Blocklisting Interim Review

05/06/2008	Elan to Present at Goldman Sachs Global Healthcare Conference
30/05/2008	Total Voting Rights
28/05/2008	Director Declaration
28/05/2008	Directors/PDMR Shareholding
23/05/2008	Directors/PDMR Shareholding
23/05/2008	Changes in Board of Directors
22/05/2008	Results of Annual General Meeting
07/05/2008	Holding in Company
30/04/2008	Total Voting Rights
24/04/2008	Elan Reports First Quarter 2008 Financial Results
18/04/2008	Elan to Present at the Morgan Stanley Global Healthcare Unplugged Conference and Host Company Day
17/04/2008	Data Presented at the 60th Annual Meeting of the American Academy of Neurology Offers Additional Support for Plasma Exchange as a Potential Tool to Accelerate TYSABRI(R) Removal
16/04/2008	Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
14/04/2008	Annual Information Document
14/04/2008	Director/PDMR Shareholding

## 2. Documents filed with United States Securities and Exchange Commission

The following documents have been filed with the US Securities and Exchange Commission and are available on the Edgar website at <http://www.sec.gov/edgar/searchedgar/webusers.htm>.

Date	Filings	Description
10/04/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
02/04/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
30/03/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
30/03/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
12/03/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
26/02/2009	20-F	Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
25/02/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
17/02/2009	SC 13G/A	[Amend]Statement of acquisition of beneficial ownership by individuals
13/02/2009	SC 13G	Statement of acquisition of beneficial ownership by individuals
10/02/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
13/01/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
12/01/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
12/01/2009	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
16/12/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
15/12/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
12/12/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
24/11/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
20/11/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
30/10/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
28/10/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
23/10/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
21/10/2008	S-8	Securities to be offered to employees in employee benefit plans
20/10/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
14/10/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
30/09/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
19/09/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
17/09/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
05/09/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]

01/08/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
31/07/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
29/07/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
24/07/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
22/07/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
22/07/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
07/07/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
17/06/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
05/06/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
22/05/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
24/04/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
18/04/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
16/04/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]
15/04/2008	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]

### 3. Documents filed with the Registrar of Companies

All of the documents listed below were filed with the Registrar of Companies in Ireland on the dates indicated. Copies of documents filed with the Registrar of Companies are available from the Companies Registration Office at [www.cro.ie](http://www.cro.ie).

Date	Filing	Description
02/04/2009	B5	Return of Allotments
12/03/2009	B5	Return of Allotments
26/02/2009	B5	Return of Allotments
21/01/2009	B5	Return of Allotments
21/01/2009	B6	Particulars of a contract relating to shares
21/01/2009	B5	Return of Allotments
14/11/2008	B5	Return of Allotments
03/11/2008	G1P	Special resolution
24/10/2008	B1C	Annual Return
24/10/2008	B1C	Account details
22/10/2008	B5	Return of Allotments
11/09/2008	B77	Authorisation of Electronic filing Agent
11/09/2008	B5	Return of Allotments
29/08/2008	B5	Return of Allotments
06/08/2008	B10	Change in Director or Secretary
17/07/2008	B5	Return of Allotments
25/06/2008	B5	Return of Allotments
13/06/2008	B10	Change in Director or Secretary
02/05/2008	B5	Return of Allotments

### 4. Annual and Interim Report 2008

The Company's Annual Report for the year ending 31 December 2008, which was filed with the Irish Stock Exchange on 31 March 2009, can be found on the Company's website [www.elan.com](http://www.elan.com), as can the Interim Report for the 6 months ended 30 June 2008 published on 28 August 2008.

A copy of this Annual Information Document and copies of the documents referred to in it can be obtained from the Company Secretary at the Company's Registered Office: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland.

#### Enquiries:

William Daniel  
Company Secretary  
+353 1 709 4000

16 April 2009